1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Tumor Necrosis Factor (TNF) Agonists -Pipeline Insights, 2016

Tumor Necrosis Factor (TNF) Agonists -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “Tumor Necrosis Factor (TNF) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Tumor Necrosis Factor (TNF) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Tumor Necrosis Factor (TNF) Agonists. DelveInsight’s Report also assesses the Tumor Necrosis Factor (TNF) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Tumor Necrosis Factor (TNF) Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Tumor Necrosis Factor (TNF) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Tumor Necrosis Factor (TNF) Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Tumor Necrosis Factor (TNF) Agonists -Pipeline Insights, 2016

- Tumor Necrosis Factor (TNF) Agonists Overview
- Tumor Necrosis Factor (TNF) Agonists Disease Associated
- Tumor Necrosis Factor (TNF) Agonists Pipeline Therapeutics
- Tumor Necrosis Factor (TNF) Agonists Therapeutics under Development by Companies
- Tumor Necrosis Factor (TNF) Agonists Filed and Phase III Products
- Comparative Analysis
- Tumor Necrosis Factor (TNF) Agonists Phase II Products
- Comparative Analysis
- Tumor Necrosis Factor (TNF) Agonists Phase I and IND Filed Products
- Comparative Analysis
- Tumor Necrosis Factor (TNF) Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Tumor Necrosis Factor (TNF) Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tumor Necrosis Factor (TNF) Agonists - Discontinued Products
- Tumor Necrosis Factor (TNF) Agonists - Dormant Products
- Companies Involved in Therapeutics Development for Tumor Necrosis Factor (TNF) Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Tumor Necrosis Factor (TNF) Agonists by Therapy Area, 2016
- Number of Products under Development for Tumor Necrosis Factor (TNF) Agonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Tumor Necrosis Factor (TNF) Agonists Assessment by Monotherapy Products
- Tumor Necrosis Factor (TNF) Agonists Assessment by Combination Products
- Tumor Necrosis Factor (TNF) Agonists Assessment by Route of Administration
- Tumor Necrosis Factor (TNF) Agonists Assessment by Stage and Route of Administration
- Tumor Necrosis Factor (TNF) Agonists Assessment by Molecule Type
- Tumor Necrosis Factor (TNF) Agonists Assessment by Stage and Molecule Type
- Tumor Necrosis Factor (TNF) Agonists Therapeutics - Discontinued Products
- Tumor Necrosis Factor (TNF) Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Tumor Necrosis Factor (TNF) Agonists by Therapy Area, 2016
- Number of Products under Development for Tumor Necrosis Factor (TNF) Agonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Tumor Necrosis Factor (TNF) Agonists Assessment by Monotherapy Products
- Tumor Necrosis Factor (TNF) Agonists Assessment by Combination Products
- Tumor Necrosis Factor (TNF) Agonists Assessment by Route of Administration
- Tumor Necrosis Factor (TNF) Agonists Assessment by Stage and Route of Administration
- Tumor Necrosis Factor (TNF) Agonists Assessment by Molecule Type
- Tumor Necrosis Factor (TNF) Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2013 - 2024

  • $ 4950
  • Industry report
  • November 2016
  • by Grand View Research

The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic ...

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese Monoclonal Antibody Diagnostic Reagents Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Monoclonal Antibody ...

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.